242 related articles for article (PubMed ID: 25695691)
1. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
DuBois SG; Chesler L; Groshen S; Hawkins R; Goodarzian F; Shimada H; Yanik G; Tagen M; Stewart C; Mosse YP; Maris JM; Tsao-Wei D; Marachelian A; Villablanca JG; Matthay KK
Clin Cancer Res; 2012 May; 18(9):2679-86. PubMed ID: 22421195
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Villablanca JG; Vo KT; Pinto N; Mosse YP; Maris JM; Shusterman S; Cohn SL; Goldsmith KC; Weiss B; Yanik GA; Twist CJ; Irwin MS; Haas-Kogan DA; Park JR; Marachelian A; Matthay KK
J Clin Oncol; 2021 Nov; 39(31):3506-3514. PubMed ID: 34270348
[TBL] [Abstract][Full Text] [Related]
6. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
7. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
DuBois SG; Allen S; Bent M; Hilton JF; Hollinger F; Hawkins R; Courtier J; Mosse YP; Matthay KK
Br J Cancer; 2015 Feb; 112(4):644-9. PubMed ID: 25602966
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
13. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
14. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
[TBL] [Abstract][Full Text] [Related]
16. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
17. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.
Matthay KK; Huberty JP; Hattner RS; Ablin AR; Engelstad BL; Zoger S; Hasegawa BH; Price D
J Nucl Biol Med (1991); 1991; 35(4):244-7. PubMed ID: 1823827
[TBL] [Abstract][Full Text] [Related]
19. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
20. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]